Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers
Combining E-602 with cemiplimab (Libtayo) established proof-of-mechanism for anti-tumor activity and tolerability in patients with PD‑L1‑resistant solid tumors, including non‑small cell lung cancer (NSCLC) and melanoma.
Combining E-602 with cemiplimab (Libtayo) established proof-of-mechanism for anti‑tumor activity and tolerability in patients with PD‑L1‑resistant solid tumors, including non‑small cell lung cancer (NSCLC) and melanoma.
The article reports early phase evidence that a novel sialidase fusion protein (E‑602) combined with the immune‑checkpoint inhibitor cemiplimab can induce anti‑tumor effects in patients whose solid tumors have become resistant to PD‑(L)1 blockade. This suggests a new therapeutic avenue for hard‑to‑treat cancers such as NSCLC and melanoma that are refractory to standard immunotherapy.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT